Sanofi Genzyme Archives -

Sanofi has added another string to its Pompe disease therapy bow, after getting FDA approval for Nexviazyme, its

Sanofi extends its Pompe range with first Nexviazyme OK

https://pharmaphorum.com/news/sanofi-extends-its-pompe-range-with-first-nexviazyme-ok/

Fresh from its takeover of Alexion, AstraZeneca has picked up a recommendation in the EU for an expansion

Boost for AZ as Ultomiris gets CHMP nod for expanded label

https://pharmaphorum.com/news/boost-for-az-as-ultomiris-gets-chmp-nod-for-expanded-label/

Shortly after failing a Parkinson’s disease study, Sanofi’s venglustat has missed the mark in another trial in autosomal

Sanofi’s venglustat bombs again, but isn’t dead yet

https://pharmaphorum.com/news/sanofis-venglustat-bombs-again-but-isnt-dead-yet/

Chiesi and Protalix have built the case for their long-acting enzyme replacement therapy (ERT) for Fabry disease PRX-102,

Switch data back Chiesi/Protalix long-acting Fabry drug

https://pharmaphorum.com/news/switch-data-back-chiesi-protalix-long-acting-fabry-drug/

Nicole Farmer, general manager, UK & Ireland at Sanofi Genzyme, tells us how the company aimed for agile

Finding agility in unprecedented times

https://pharmaphorum.com/views-analysis-patients/finding-agility-in-unprecedented-times/

Marc Moodley has worked at Sanofi since 2018 and is the new medical head, UK and Ireland for

Sanofi Genzyme UK medical boss Marc Moodley discusses oncology plans, NICE and Brexit

https://pharmaphorum.com/views-analysis-oncology/sanofi-genzyme-uk-medical-boss-marc-moodley-discusses-oncology-plans-nice-and-brexit/

Sanofi Genzyme